LB-011 - ENCOURAGING PHARMACOKINETIC (PK)/PHARMACODYNAMIC (PD) RESULTS OF SUBCUTANEOUS (SC) BLINATUMOMAB IN RELAPSED OR REFRACTORY (R/R) INDOLENT NON-HODGKIN’S LYMPHOMA (I-NHL) AND R/R ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS (PTS) INDICATE THAT PATIENT CONVENIENT SC DOSING IS A VIABLE ALTERNATIVE TO CONTINUOUS INTRAVENOUS INFUSION (CIV) DOSING.
H. Wong1, F. Chandra2, G. Zugmaier3, P. Gordon2, Y. Zeng2, S. Doshi2, S. Dutta2, V. Upreti1; 1Amgen, South San Francisco, CA, USA, 2Amgen, Thousand Oaks, CA, USA, 3Amgen, Munich, Germany.